189 related articles for article (PubMed ID: 23528042)
1. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.
Waters EK; Genga RM; Thomson HA; Kurz JC; Schaub RG; Scheiflinger F; McGinness KE
J Thromb Haemost; 2013 Jun; 11(6):1137-45. PubMed ID: 23528042
[TBL] [Abstract][Full Text] [Related]
2. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Dockal M; Hartmann R; Fries M; Thomassen MC; Heinzmann A; Ehrlich H; Rosing J; Osterkamp F; Polakowski T; Reineke U; Griessner A; Brandstetter H; Scheiflinger F
J Biol Chem; 2014 Jan; 289(3):1732-41. PubMed ID: 24275667
[TBL] [Abstract][Full Text] [Related]
3. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
4. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
[TBL] [Abstract][Full Text] [Related]
5. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
7. Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.
Thomassen S; Mastenbroek TG; Swieringa F; Winckers K; Feijge MAH; Schrijver R; Cosemans JMEM; Maroney SA; Mast AE; Hackeng TM; Heemskerk JWM
Thromb Haemost; 2018 Mar; 118(3):502-513. PubMed ID: 29452445
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
9. The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII--tissue factor complex.
Ndonwi M; Broze G; Bajaj SP
J Thromb Haemost; 2005 Jan; 3(1):112-8. PubMed ID: 15634274
[TBL] [Abstract][Full Text] [Related]
10. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Gissel M; Orfeo T; Foley JH; Butenas S
Thromb Res; 2012 Dec; 130(6):948-55. PubMed ID: 22951415
[TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
Chang JY; Chantrathammachart P; Monroe DM; Key NS
Thromb Res; 2012 Sep; 130(3):e151-7. PubMed ID: 22658294
[TBL] [Abstract][Full Text] [Related]
12. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Chowdary P
Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
[TBL] [Abstract][Full Text] [Related]
13. The effect of leukocyte elastase on tissue factor pathway inhibitor.
Higuchi DA; Wun TC; Likert KM; Broze GJ
Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
[TBL] [Abstract][Full Text] [Related]
14. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor pathway.
McVey JH
Baillieres Clin Haematol; 1994 Sep; 7(3):469-84. PubMed ID: 7841596
[TBL] [Abstract][Full Text] [Related]
16. Zn²(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor.
Fernandes N; Mosnier LO; Tonnu L; Heeb MJ
J Thromb Haemost; 2010 Sep; 8(9):1976-85. PubMed ID: 20492471
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
18. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
20. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.
Parunov LA; Fadeeva OA; Balandina AN; Soshitova NP; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
J Thromb Haemost; 2011 Sep; 9(9):1825-34. PubMed ID: 21696535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
